HiSCR (Hidradenitis Suppurativa Clinical Response): a novel clinical endpoint to evaluate therapeutic outcomes in patients with hidradenitis suppurativa from the placebo‐controlled portion of a phase 2 adalimumab study

BACKGROUND: Determining treatment response for patients with hidradenitis suppurativa (HS) can be challenging due to limitations of current disease activity evaluations. OBJECTIVE: Evaluate the novel, validated endpoint, Hidradenitis Suppurativa Clinical Response (HiSCR) and its utility as an outcom...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:J Eur Acad Dermatol Venereol
Hlavní autoři: Kimball, A.B., Sobell, J.M., Zouboulis, C.C., Gu, Y., Williams, D.A., Sundaram, M., Teixeira, H.D., Jemec, G.B.E.
Médium: Artigo
Jazyk:Inglês
Vydáno: John Wiley and Sons Inc. 2015
Témata:
Original Articles and Short Reports
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC5034809/
https://ncbi.nlm.nih.gov/pubmed/26201313
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/jdv.13216
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky